Description
I am a member of the OPTIMA Trial Management Group and Surgical Lead for this national UK NIHR-funded study looking at the use of multiparameter testing to guide chemotherapy use in women with breast cancer. The TMG oversees the delivery of the trial, and I provide advice and expertise to the study regarding all aspects of the surgical treatment of enrolled patients. OPTIMA has currently recruited ~2500 of its target 4000 patients.| Period | 2017 → … |
|---|---|
| Held at | OPTIMA Trial Management Group, United Kingdom |
| Degree of Recognition | National |
Documents & Links
Related content
-
Research output
-
Abstract OT1-06-01: OPTIMA: A prospective randomized trial to validate the predictive utility and cost-effectiveness of gene expression test-directed chemotherapy decisions in early breast cancer
Research output: Contribution to conference › Abstract › peer-review
-
Abstract OT3-17-01: OPTIMA: A prospective randomized trial to validate the clinical utility and cost-effectiveness of gene expression test-directed chemotherapy decisions in mostly node-positive early breast cancer
Research output: Contribution to journal › Meeting abstract › peer-review